NCT04009083View on ClinicalTrials.gov

Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

January 7, 2021

Study Completion Date

January 7, 2021

Conditions
Prostate Cancer
Interventions
DEVICE

Standard of Care MRI

Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies

OTHER

Fluciclovine PET scan added to MRI

18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT04009083 - Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA) | Biotech Hunter | Biotech Hunter